Photo from wikipedia
Key Points Question Is subcutaneous treatment with casirivimab and imdevimab associated with improved 28-day clinical outcomes compared with nontreatment, and is it clinically similar to intravenously administered casirivimab and imdevimab… Click to show full abstract
Key Points Question Is subcutaneous treatment with casirivimab and imdevimab associated with improved 28-day clinical outcomes compared with nontreatment, and is it clinically similar to intravenously administered casirivimab and imdevimab for outpatients with COVID-19? Findings In this cohort study of 1959 propensity-matched outpatients with mild to moderate COVID-19 symptoms, the 28-day rate of hospitalization or death was 3.4% vs 7.0% for those receiving subcutaneous treatment vs nontreatment. In a second cohort analysis of 2185 outpatients, the 28-day rate of hospitalization or death was 2.8% vs 1.7% for subcutaneous vs intravenous treatment. Meaning Subcutaneous casirivimab and imdevimab was associated with reduced hospitalization and death compared with nontreatment and showed similar outcomes compared with intravenous casirivimab and imdevimab in outpatients with COVID-19.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!